Drugmakers May Turn to Bankruptcy to Lessen Opioid Liability
Share
Drugmakers May Turn to Bankruptcy to Lessen Opioid Liability
By Kirk B. Burkley, Managing Partner, Bernstein-Burkley
The U.S. opioid crisis and the avalanche of lawsuits it has produced may lead numerous pharmaceutical companies to seek bankruptcy relief, perhaps rivaling the asbestos bankruptcies of the late 1990s and early 2000s.
New legal actions are being filed against pharmaceutical manufacturers...
We hope you enjoyed your free content!
To continue, please become a TMA member.
Access the Journal of Corporate Renewal and other content in the Learning Link.
Become part of a global organization of turnaround and restructuring professionals with 54 Chapters and more than 400 events each year.
Build your personal brand and professional network with opportunities to connect, speak, lead, and win awards.
Kirk Burkley is a managing partner with Bernstein-Burkley. His experience includes representing secured and unsecured creditors in bankruptcy, financial restructuring, and workout situations, including the representation of unsecured creditors’ committees, equipment lessors, financial institutions, and commercial landlords. Burkley is certified in business bankruptcy and creditors’ rights law from the American Board of Certification. His accolades include being named a “Super Lawyer” since 2013 and one of “The Best Lawyers in America” since 2011.
